Liquid biopsy start-up Grail Inc. announced that in a study of almost 6,700 participants, its blood test could detect more than 50 types of cancer, including 12 very dangerous types of cancers, with a low false-positive rate, indicating it could be useful for screening patients.
The sub-study from the company’s 15,000-patient Circulating Cell-free Genome Atlas (CCGA) study analyzed cell-free DNA from normal and cancerous...